AmCad BioMed Corporation
AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases. The company's products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO for detection of obstructive sleep apnea on awake patients. It also developing AmCAD-US, … Read more
AmCad BioMed Corporation (4188) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.026x
Based on the latest financial reports, AmCad BioMed Corporation (4188) has a cash flow conversion efficiency ratio of -0.026x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($U-15.49 Million) by net assets ($U600.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
AmCad BioMed Corporation - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how AmCad BioMed Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
AmCad BioMed Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AmCad BioMed Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Airtime Partecipazioni SpA
PA:ALMEX
|
0.201x |
|
Robit Oyj
HE:ROBIT
|
0.042x |
|
Huron Valley Bancorp Inc
PINK:HVLM
|
N/A |
|
Samil Co.Ltd
KQ:032280
|
0.015x |
|
Hawsons Iron Ltd
AU:HIO
|
-0.015x |
|
PT MNC Energy Investments Tbk
JK:IATA
|
0.041x |
|
Delta Israel Brands Ltd
TA:DLTI
|
0.165x |
|
Pacgold Ltd
AU:PGO
|
-0.030x |
Annual Cash Flow Conversion Efficiency for AmCad BioMed Corporation (2021–2025)
The table below shows the annual cash flow conversion efficiency of AmCad BioMed Corporation from 2021 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $U600.82 Million | $U-47.06 Million | -0.078x | -0.27% |
| 2024-12-31 | $U663.72 Million | $U-51.85 Million | -0.078x | +10.24% |
| 2023-12-31 | $U477.95 Million | $U-41.60 Million | -0.087x | -32.31% |
| 2022-12-31 | $U519.78 Million | $U-34.19 Million | -0.066x | +2.25% |
| 2021-12-31 | $U579.03 Million | $U-38.97 Million | -0.067x | -- |